Drugs Manufacturer from Hyderabad on overdrive

Optimus Pharma gets DCGI nod for conducting Phase III Clinical Trials for Molnupiravir on patients with mild and moderate COVID-19 infection

Hyderabad (Telangana) [India], May 19: Optimus Pharma on Tuesday received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild and Moderate Covid-19 symptoms. With a severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.

Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI. The regulator gave a nod for conducting the trial on mild and moderate patients on May 18 2021.

As per the clinical trial, protocols approved, a total of 2500 subjects in both mild and moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of 05 days and the total study duration will be a maximum for 29 days from randomisation, the release said.

“Optimus is all geared to immediately begin clinical trials on Molnupiravir on COVID-19 patients in India. The clinical trial will let us know the efficacy of this molecule on COVID-19 patients,” Chairman & Managing Director – Dr. D Srinivas Reddy said.

In the previous press release, the company stated that Molnupiravir demonstrated highly promising results in reducing viral load to 0.0% in merely 5 days of treatment duration. Based on completed phase 2 part clinical studies, the proposed dosage is 800mg twice daily which significantly reduces viral culture in infected patients not progressing into ARDS.

Optimus Pharma is one of the largest manufacturers of the highly successful SARS-CoV-2 antiviral drug without compromising on quality as is the case with Favipiravir (sold under the brand – FAVICOVID).  The company aims to do the same with Molnupiravir to cater to the rising demand for Anti-Viral drugs against SARS-CoV-2 in the Indian market.

With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Cloudphysician’s Smart-ICU Solution provides access to India’s best intensivists to hospitals across India using technology

(L to R) Dr. Dileep Raman, Co-founder & Chief of Healthcare, Cloudphysician, Dr. Arindam Kar, Organizing Secretary, CRITICARE, Dr. Dhruv Joshi, Co-founder & CEO, Cloudphysician April 9: Cloudphysician, a new age technology enabled healthcare delivery company has developed and deployed a Smart-ICU platform to manage ICU patients in hospitals across India. Highly trained Cloudphysician intensivists 24×7 […]

Read More
Health

SimpliHealth simplifies the concept of health

April 9: Days like World Health Day come to remind us that Health is the greatest wealth. In the age of the health information tsunami, the team of SimpliHealth reached out to doctors and health experts to reinforce the importance of health and break some conventional myths or myths created by Google. With the years-long […]

Read More
Health

SRV Hospitals and Lokmanya Hospital collaborate to launch a New Centre of Excellence in Robotic Orthopaedics

SRV Hospitals and Lokmanya Hospitals alliance becomes the first and foremost to have 4 Robots to provide efficient real-intelligence hand-held robotics solution for joint replacement surgeries  Mumbai (Maharashtra) [India], April 1: SRV hospitals group in association with Lokmanya Hospital, Pune has launched a new centre of excellence in Robotic orthopedics under the umbrella of “SRV […]

Read More